[go: up one dir, main page]

CL2007002386A1 - Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica. - Google Patents

Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.

Info

Publication number
CL2007002386A1
CL2007002386A1 CL2007002386A CL2007002386A CL2007002386A1 CL 2007002386 A1 CL2007002386 A1 CL 2007002386A1 CL 2007002386 A CL2007002386 A CL 2007002386A CL 2007002386 A CL2007002386 A CL 2007002386A CL 2007002386 A1 CL2007002386 A1 CL 2007002386A1
Authority
CL
Chile
Prior art keywords
diabetic
dihydroxybenzene
neovascularization
cornea
retina
Prior art date
Application number
CL2007002386A
Other languages
English (en)
Inventor
Saenz De Tejada Gorman Inigo
Valverde Lopez Serafin
Maria Lozano Puerto Rosa
Gimenez Gall Guillermo
Cuevas Sanchez Pedro
Original Assignee
Action Medicines Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ES200602217A external-priority patent/ES2315117B1/es
Application filed by Action Medicines Sl filed Critical Action Medicines Sl
Publication of CL2007002386A1 publication Critical patent/CL2007002386A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneración macular, neovascularización o angiogénesis de la cornea, iris o retina, retinopatía proliferativa diabética y no diabética.
CL2007002386A 2006-08-16 2007-08-16 Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica. CL2007002386A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200602217A ES2315117B1 (es) 2006-08-16 2006-08-16 Uso de derivados 2,5-dihidroxibencenicos en la preparacion de medicamentos utiles en el tratamiento de asma.
ES200701855 2007-07-02

Publications (1)

Publication Number Publication Date
CL2007002386A1 true CL2007002386A1 (es) 2008-01-18

Family

ID=38515369

Family Applications (5)

Application Number Title Priority Date Filing Date
CL2007002392A CL2007002392A1 (es) 2006-08-16 2007-08-16 Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hiperplasia prostatica benigna, enfermedad de barrett, asma, enfermedad de crohn, reparacion de musculo esqueletico y tendon, colitis ulcerosa y leishmaniasis.
CL2007002385A CL2007002385A1 (es) 2006-08-16 2007-08-16 Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de infeccion por helicobacter pylori, pterigion, endometriosis, sindrome de hiperestimulacion ovarica y enfermedad del rinon poliquistico.
CL2007002386A CL2007002386A1 (es) 2006-08-16 2007-08-16 Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
CL2007002388A CL2007002388A1 (es) 2006-08-16 2007-08-16 Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas.
CL2007002387A CL2007002387A1 (es) 2006-08-16 2007-08-16 Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CL2007002392A CL2007002392A1 (es) 2006-08-16 2007-08-16 Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hiperplasia prostatica benigna, enfermedad de barrett, asma, enfermedad de crohn, reparacion de musculo esqueletico y tendon, colitis ulcerosa y leishmaniasis.
CL2007002385A CL2007002385A1 (es) 2006-08-16 2007-08-16 Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de infeccion por helicobacter pylori, pterigion, endometriosis, sindrome de hiperestimulacion ovarica y enfermedad del rinon poliquistico.

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2007002388A CL2007002388A1 (es) 2006-08-16 2007-08-16 Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas.
CL2007002387A CL2007002387A1 (es) 2006-08-16 2007-08-16 Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.

Country Status (8)

Country Link
US (2) US9060966B2 (es)
EP (3) EP2056805B1 (es)
AR (5) AR062396A1 (es)
AT (2) ATE509621T1 (es)
CL (5) CL2007002392A1 (es)
ES (1) ES2495965T3 (es)
PT (3) PT2056805E (es)
WO (5) WO2008020032A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2238924B1 (es) * 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
US20070149618A1 (en) 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
US20080125485A1 (en) 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
US8541467B2 (en) 2006-08-16 2013-09-24 Action Medicines, S.L. Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ
WO2009103069A1 (en) 2008-02-15 2009-08-20 Osborne David W Skin penetration enhancing systems for polar drugs
FR2951085B1 (fr) * 2009-10-09 2012-05-18 Inst Substances Vegetales Utilisation de composes phenoliques pour la deglycation des proteines
ES2385160B1 (es) * 2010-12-23 2013-05-24 Italfármaco, S.A. Compuestos con actividad inhibitoria de factores de crecimiento de fibroblastos.
EP2777699B1 (en) * 2012-02-02 2017-03-29 Invesfovea S.L. Diethylamine-2,5-dihydroxybenzenesulfonate for the treatment of age-related macular degeneration
PL404138A1 (pl) * 2013-05-31 2014-12-08 Warszawski Uniwersytet Medyczny Pochodne kwasu benzoesowego jako inhibitory receptora IL-15Rα
PT3167881T (pt) * 2015-10-19 2019-12-05 Dobecure S L Etamsilato administrado localmente como medicamento

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115648A (en) * 1974-09-13 1978-09-19 Laboratorios Del Dr. Esteve, S.A. 2,5-Dihydroxy benzene sulfonic acid mono esters
US4513007A (en) * 1983-05-03 1985-04-23 Laboratoires Om Sa Method for treating heart disease
US4617311A (en) * 1985-05-17 1986-10-14 Eli Lilly And Company Antiasthmatic method
CH679372A5 (es) * 1989-04-07 1992-02-14 Vet Gerhard Stuker Dr Med
CH682716A5 (de) * 1992-01-13 1993-11-15 Christian Fricker Benzo-Pyrone und/oder Dobesilat-Calcium enthaltende pharmazeutische Zusammensetzung.
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5374772A (en) * 1992-12-08 1994-12-20 Hoffmann-Laroche Inc. Substituted benzoic acids, inhibitors of phospholipases A2
US5798356A (en) * 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
BR9807330A (pt) * 1997-02-14 2000-04-18 Kissei Pharmaceutical Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
CZ20012038A3 (cs) * 1998-12-23 2001-09-12 Idea Ag Zdokonalený přípravek pro topické, neinvazivní použití in vivo
JP2000256259A (ja) * 1999-03-11 2000-09-19 Nippon Zoki Pharmaceut Co Ltd メイラード反応阻害剤
CA2371728C (en) * 1999-06-11 2009-06-02 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US20020037897A1 (en) * 2000-08-07 2002-03-28 3-Dimensional Pharmaceuticals, Inc. Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
JP2002193800A (ja) * 2000-12-22 2002-07-10 Taisho Pharmaceut Co Ltd Ｖｅｇｆ受容体拮抗剤
BR0207706A (pt) * 2001-02-28 2004-03-23 Melacure Therapeutics Ab ésteres de diaminoquinazolina para uso como inibidores da diidrofolato redutase
WO2003016265A1 (en) * 2001-08-17 2003-02-27 Eisai Co., Ltd. Cyclic compound and ppar agonist
WO2003024452A1 (de) * 2001-09-14 2003-03-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue arzneimittel zur inhalation
WO2004004648A2 (en) * 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
RU2002120366A (ru) * 2002-08-01 2005-02-27 БиоДием Лимитед (AU) Новые производные имидазолия и фармацевтические композиции на их основе
CA2497901A1 (en) * 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
ES2208123A1 (es) * 2002-11-29 2004-06-01 Laboratorios Del Dr. Esteve, S.A. Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.
AU2003212672A1 (en) * 2003-01-29 2004-08-23 Dal-Hoon Son Pharmaceutical composition comprising an extract or compounds isolated from elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
EP1653939A2 (en) * 2003-08-07 2006-05-10 Allergan, Inc. Method for treating cachexia with retinoid ligands
GB0321228D0 (en) * 2003-09-10 2003-10-08 Inpharmatica Ltd Modulating cell activity
JP2007522079A (ja) * 2003-10-31 2007-08-09 エラン ファーマ インターナショナル リミテッド ニメスリド組成物
US20050222247A1 (en) * 2003-12-13 2005-10-06 Bayer Healthcare Ag Chroman derivatives
EP1836160A1 (en) * 2004-12-24 2007-09-26 CTG Pharma S.r.l. Compounds for treating metabolic syndrome
EP1676573A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
EP1749820A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Salts of substituted pyrazoline compounds, their preparation and use as medicaments
US20080279932A1 (en) * 2005-08-04 2008-11-13 Jean-Louis Reber Compounds
CN100506804C (zh) * 2006-01-26 2009-07-01 于学敏 羟苯磺酸烷基吡嗪药物及其制备方法和应用
US20070196350A1 (en) * 2006-02-22 2007-08-23 Bartels Stephen P Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
WO2007113855A1 (en) * 2006-03-30 2007-10-11 Council Of Scientific & Industrial Research A bioactive fraction from zingiber officinale and a process for the preparation thereof

Also Published As

Publication number Publication date
EP2054045B1 (en) 2011-05-18
CL2007002388A1 (es) 2008-01-18
WO2008020032A8 (en) 2008-04-17
WO2008020032A1 (en) 2008-02-21
CL2007002385A1 (es) 2008-01-18
US20110152222A1 (en) 2011-06-23
ES2495965T3 (es) 2014-09-17
EP2054045A1 (en) 2009-05-06
EP2056804A1 (en) 2009-05-13
AR062390A1 (es) 2008-11-05
PT2054045E (pt) 2011-08-31
AR062395A1 (es) 2008-11-05
PT2056805E (pt) 2011-09-02
EP2056804B1 (en) 2013-05-22
WO2008020034A1 (en) 2008-02-21
WO2008020033A1 (en) 2008-02-21
US9060966B2 (en) 2015-06-23
AR062393A1 (es) 2008-11-05
AR062399A1 (es) 2008-11-05
EP2056805B1 (en) 2011-05-25
ATE509621T1 (de) 2011-06-15
PT2056804E (pt) 2014-07-11
WO2008020031A1 (en) 2008-02-21
CL2007002392A1 (es) 2008-01-18
WO2008020042A1 (en) 2008-02-21
AR062396A1 (es) 2008-11-05
US20080114063A1 (en) 2008-05-15
EP2056805A1 (en) 2009-05-13
ATE510536T1 (de) 2011-06-15
CL2007002387A1 (es) 2008-01-18

Similar Documents

Publication Publication Date Title
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.
MX2007008848A (es) Metodos y composiciones para el tratamiento de desordenes oculares.
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
CR10041A (es) Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares
EP2156833A4 (en) PROPHYLACTIC OR THERAPEUTIC AGENT FOR POSTERIOR EYES DISEASE WITH SELF-SELECTIVE NON-ERGOT D2 RECEPTOR AGONIST AS AN ACTIVE SUBSTANCE
BRPI0516377A (pt) inibição de rnai de ctgf para tratamento de distúrbios oculares
AR054229A1 (es) Metodos para tratar la angiogenesis ocular edema de retina, isquemia de retina y retinopatia diabetica usando inhibidores selectivos de rtk
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
MX2009001745A (es) Tratamiento de enfermedades oculares.
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
EP3606570B8 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
UY33153A (es) Formulación tópica oftálmica de péptidos
ATE412414T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von proliferativen krankheiten oder entzündungen
DK2319517T3 (da) Anvendelse af prodrugs til okulær, intravenøs administration
CL2007003836A1 (es) Uso de compuestos derivados de isosorbide en la prevencion y/o tratamiento de enfermedades oftalmologicas mediadas por hipertension ocular, tales como glaucoma.
WO2007089673A8 (en) Compositions and methods for treatment of ophthalmic diseases and disorders
EA200700772A1 (ru) Аналоги полиаминов в качестве терапевтических средств для глазных заболеваний
BR0314419A (pt) Compostos de 5-croman-5-il-etilamina substituìdos, seu uso e composição farmacêutica incluindo-o
AU2018240462A1 (en) Drugs and compositions for the treatment of ocular disorders
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas
CL2011001812A1 (es) Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras.
BRPI0811223A2 (pt) Métodos para modular uma inflamação em um paciente, e para tratar, controlar, reduzir ou melhorar uma infecção ocular ou oftálmica e uma sequela inflamatória da mesma, uso de uma fluoroquinolona, e, composição farmacêutica.
MX2023012758A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular asociada con angiogenesis.